Dear Reader :

New Year greetings and we wish you a happy and prosperous 2024!

This month’s newsletter, co-developed by the IPA and Citeline, brings you the key takeaways from the marquee J.P. Morgan Healthcare Conference. Besides big M&A announcements, we encapsulate other commentary that sets the tone for the year ahead.

We tell you why 2023 wasn’t a good year for Pfizer and there’s also Organon’s expectations of a tidal wave of biosimilar competition in 2028.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
Perspective From Industry Leaders
Organon Expects 2028 ‘Tidal Wave’ For Biosimilars J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology
Organon Expects 2028 ‘Tidal Wave’ For Biosimilars J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology

Organon CEO Kevin Ali provided a detailed overview of the firm’s biosimilars strategy at the J.P. Morgan...

Daily notebook from the J.P. Morgan Healthcare Conference: Biogen is still looking for deals, just smaller...
Licensing & Collaboration Agreements
J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth J.P. Morgan Day Four: Roche Sees Lots Of Partnering Interest, While Bluebird, Sage Offer Launch Updates
J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth J.P. Morgan Day Four: Roche Sees Lots Of Partnering Interest, While Bluebird, Sage Offer Launch Updates

Daily notebook from the J.P. Morgan Healthcare Conference: Deal and strategy news from Novartis...

Daily notebook from the J.P. Morgan Healthcare Conference: Roche expects continued high interest in...
Next Gen R&D
Hematologists Consider Where New Therapies Fit In Sickle Cell Treatment Paradigm Sickle Cell Drug Development Gains Momentum Across Disease Spectrum
Hematologists Consider Where New Therapies Fit In Sickle Cell Treatment Paradigm Sickle Cell Drug Development Gains Momentum Across Disease Spectrum

The first gene editing medicine and gene therapy for sickle cell disease were approved as the ASH meeting got...

The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease...
Clinical Trials
Longboard Surfs PACIFIC Waves To Pivotal Phase III Epilepsy Program Trials In Focus: Joint Venture Aims To Simplify Cell Therapy Trials For Smaller Players
Longboard Surfs PACIFIC Waves To Pivotal Phase III Epilepsy Program Trials In Focus: Joint Venture Aims To Simplify Cell Therapy Trials For Smaller Players

The company’s valuation quadrupled after it announced positive Phase Ib/IIa results for bexicaserin in....

CTMC CEO Jason Bock talked to Scrip about the venture between MD Anderson and National Resilience...
Citeline Contact

Poornachandra Tejasvi .K,
Senior Director - Emerging Markets, India
Mobile: +91 9945273146
Email: poornachandra.tejasvi@citeline.com
Client Services: clientservices@citeline.com

alt_text   alt_text 		IPA Contact

Name: Hari Pranav K
Email: haripranav.k@ipa-india.org